

1. **Papadakos SP**, Arvanitakis K, Stergiou IE, Koutsompina ML, Germanidis G, Theocharis S.  $\gamma\delta$  T Cells: A Game Changer in the Future of Hepatocellular Carcinoma Immunotherapy. *Int J Mol Sci.* 2024 Jan 23;25(3):1381.
2. **Papadakos SP**, Argyrou A, Lekakis V, Arvanitakis K, Kalisperati P, Stergiou IE, Konstantinidis I, Schizas D, Koufakis T, Germanidis G, Theocharis S. Metformin in Esophageal Carcinoma: Exploring Molecular Mechanisms and Therapeutic Insights. *Int J Mol Sci.* 2024 Mar 4;25(5):2978.
3. **Mastrogeorgiou M**, **Chatzikalil E**, Theocharis S, Papoudou-Bai A, Péoc'h M, Mobarki M, Karpathiou G. The immune microenvironment of cancer of the uterine cervix. *Histol Histopathol.* 2024 (ahead print /in press)
4. **Papadakos SP**, **Chatzikalil E**, Arvanitakis K, Vakadaris G, Stergiou IE, Koutsompina ML, Argyrou A, Lekakis V, Konstantinidis I, Germanidis G, Theocharis S. Understanding the Role of Connexins in Hepatocellular Carcinoma: Molecular and Prognostic Implications. *Cancers (Basel).* 2024 Apr 17;16(8):1533.
5. **Papadakos SP**, **Chatzikalil E**, Vakadaris G, Reppas L, Arvanitakis K, Koufakis T, Siakavellas SI, Manolakopoulos S, Germanidis G, Theocharis S. Exploring the Role of GITR/GITRL Signaling: From Liver Disease to Hepatocellular Carcinoma. *Cancers (Basel).* 2024 Jul 22;16(14):2609.
6. **Chatzikalil E**, Stergiou IE, **Papadakos SP**, Konstantinidis I, Theocharis S The Clinical Relevance of the EPH/Ephrin Signaling Pathway in Pediatric Solid and Hematologic Malignancies. *Int J Mol Sci.* 2024 Mar 29;25(7):3834.
7. Tsiakanikas P, Athanasopoulou K, Darioti IA, **Agiassoti VT**, Theocharis S, Scorilas A, Adamopoulos PG. Beyond the Chromosome: Recent Developments in Decoding the Significance of Extrachromosomal Circular DNA (eccDNA) in Human Malignancies. *Life (Basel).* 2024 Jul 24;14(8):922.
8. Stergiou IE, Palamaris K, Levidou G, **Tzimou M**, Papadakos SP, Mandrakis G, Masaoutis C, Rontogianni D, Theocharis S. PD-L1 Expression in Neoplastic and Immune Cells of Thymic Epithelial Tumors: Correlations with Disease Characteristics and HDAC Expression. *Biomedicines.* 2024 Mar 31;12(4):772.
9. **Papadakos SP**, Arvanitakis K, Stergiou IE, Vallilas C, Sougioultzis S, Germanidis G, Theocharis S. Interplay of Extracellular Vesicles and TLR4 Signaling in Hepatocellular Carcinoma Pathophysiology and Therapeutics. *Pharmaceutics.* 2023 Oct 13;15(10):2460.

10. **Papadakos SP**, Machairas N, Stergiou IE, Arvanitakis K, Germanidis G, Frampton AE, Theocharis S. Unveiling the Yin-Yang Balance of M1 and M2 Macrophages in Hepatocellular Carcinoma: Role of Exosomes in Tumor Microenvironment and Immune Modulation. *Cells*. 2023 Aug 10;12(16):2036.
11. **Papadakos SP**, Ferraro D, Carbone G, Frampton AE, Vennarecci G, Kykalos S, Schizas D, Theocharis S, Machairas N. The Emerging Role of Metformin in the Treatment of Hepatocellular Carcinoma: Is There Any Value in Repurposing Metformin for HCC Immunotherapy? *Cancers (Basel)*. 2023 Jun 13;15(12):3161.
12. Arvanitakis K, **Papadakos SP**, Lekakis V, Koufakis T, Lempesis IG, Papantoniou E, Kalopitas G, Georgakopoulou VE, Stergiou IE, Theocharis S, Germanidis G. Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches. *Int J Mol Sci*. 2023 Sep 28;24(19):14704.
13. **Papadakos SP**, **Dedes N**, Gkolemi N, Machairas N, Theocharis S. The EPH/Ephrin System in Pancreatic Ductal Adenocarcinoma (PDAC): From Pathogenesis to Treatment. *Int J Mol Sci*. 2023 Feb 3;24(3):3015.
14. **Alexandris D**, Alevizopoulos N, Palamaris K, Gakiopoulou C, Theocharis S. Pinnae and facial hypertrichosis induced by cetuximab. *J Oncol Pharm Pract*. 2023 Apr;29(3):731.
15. **Papadakos SP**, Arvanitakis K, Stergiou IE, Lekakis V, Davakis S, Christodoulou MI, Germanidis G, Theocharis S. The Role of TLR4 in the Immunotherapy of Hepatocellular Carcinoma: Can We Teach an Old Dog New Tricks? *Cancers (Basel)*. 2023 May 17;15(10):2795.
16. Stergiou IE, **Papadakos SP**, **Karyda A**, Tsitsilonis OE, Dimopoulos MA, Theocharis S. EPH/Ephrin Signaling in Normal Hematopoiesis and Hematologic Malignancies: Deciphering Their Intricate Role and Unraveling Possible New Therapeutic Targets. *Cancers (Basel)*. 2023 Aug 4;15(15):3963.
17. **Alexandris D**, Alevizopoulos N, Gakiopoulou H, Stavrinou N, Vourlakou C. Cutaneous Stevens Johnson - Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients. *J Oncol Pharm Pract*. 2022 Jan 18:10781552221074623.
18. **Alexandris D**, Alevizopoulos N, Marinos L, Kanellis G, Gakiopoulou C. Lichenoid drug eruption associated with imatinib mesylate therapy. *J Oncol Pharm Pract*. 2022 Apr 27:10781552221096846.
19. Palamaris K, **Alexandris D**, Stylianou K, Giatras I, Stofas A, Kaitatzoglou C, Migkou M, Goutas D, Psimenou E, Theodoropoulou E, Theocharis S, Alevizopoulos N, Kastritis E, Gerakis A, Gakiopoulou C.

Immune checkpoint inhibitors associated renal toxicity: a series of 12 cases. *H Journal of Clinical Medicine* 2022 Aug;16(11):4786.

20. **Papadakos SP**, Petrogiannopoulos L, Pergaris A, Theocharis S. The EPH/Ephrin System in Colorectal Cancer. *Int J Mol Sci.* 2022 Mar 2;23(5):2761.
21. **Papadakos SP**, Dedes N, Pergaris A, Gazouli M, Theocharis S. Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment? *Int J Mol Sci.* 2022 Mar 25;23(7):3620.
22. **Papadakos SP**, Dedes N, Kouroumalis E, Theocharis S. The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity. *Cancers (Basel).* 2022 Jun 27;14(13):3150.
23. **Papadakos SP**, Tsagkaris C, Papadakis M, Papazoglou AS, Moysidis DV, Zografos CG, Theocharis S. Angiogenesis in gastrointestinal stromal tumors: From bench to bedside. *World J Gastrointest Oncol.* 2022 Aug 15;14(8):1469.
24. **Skandalaki A**, Sarantis P, Theocharis S. Pregnane X Receptor (PXR) Polymorphisms and Cancer Treatment. *Biomolecules.* 2021 Aug 2;11(8):1142.
25. Psilopatis I, **Chronopoulou E**, Vrettou K, Troungos C, Theocharis S. EPH/Ephrin-Targeting Treatment in Breast Cancer: A New Chapter in Breast Cancer Therapy. *Int J Mol Sci.* 2022 Dec 3;23(23):15275.
26. Theocharis S, Giaginis C, **Gourzi S**, Alexandrou P, Tsourouflis G, Sarantis P, Danas E, Michail A, Tsoukalas N, Pergaris A, Politis PK, Nakopoulou L. High Pregnane X Receptor (PXR) Expression Is Correlated with Poor Prognosis in Invasive Breast Carcinoma. 2021 Oct 20;11(11):1946.
27. Palamaris K, **Moutafi M**, Gakiopoulou H and Theocharis S. Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma. *Int J Mol Sci.* 2022 Mar 27;23(7):3660.